Navigation Links
VELCADE(R) (Bortezomib) for Injection Based Treatment Delivers Impressive Complete Response and Survival in Patients With Newly Diagnosed Multiple Myeloma
Date:5/31/2008

t is 70 years), recent statistics indicate both increasing incidence and younger age of onset. In the U.S., more than 50,000 individuals have MM and 20,000 new cases are diagnosed each year. Worldwide there are approximately 74,000 new cases and over 45,000 deaths annually.

About VELCADE

VELCADE is being co-developed by Millennium Pharmaceuticals, The Takeda Oncology Company, and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. and Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in 85 countries worldwide. More than 100,000 patients have been treated with VELCADE globally.

In the U.S., VELCADE is indicated for the treatment of patients with multiple myeloma who have received at least one prior therapy. VELCADE is also indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron or mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of antineoplastic therapy. In the European Union and many other countries worldwide, VELCADE is approved for patients with multiple myeloma after first relapse.

Risks associated with VELCADE therapy include new or worsening peripheral neuropathy, hypotension observed throughout therapy, cardiac and pulmonary disorders, gastrointestinal adverse events, thrombocytopenia, neutropenia and tumor lysis syndrome. Women of childbearing potential should avoid becoming pregnant while being treated with VELCADE. Cases of severe sensory and motor peripheral neuropathy have been reported. The long-term outcome of peripheral neurop
'/>"/>

SOURCE Millennium Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
3. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
4. New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma
5. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
6. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
7. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
8. Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Inclusion of Six-Year Overall Survival Data in the Eloxatin(R) (oxaliplatin injection) Prescribing Information Granted FDA Priority Review
11. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... EntreMed, Inc. (Nasdaq: ENMD ), ... treatment of cancer, today reported results for the ... (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO) ... for the third quarter of 2010 of ($2.1 ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), a ... for cardiovascular disease, today announced its third quarter financial results ... ended September 30, 2010, Nile reported a net loss of ... net loss of approximately $2.0 million, or $0.08 per share, ...
Cached Medicine Technology:EntreMed Reports Third Quarter 2010 Financial Results 2EntreMed Reports Third Quarter 2010 Financial Results 3EntreMed Reports Third Quarter 2010 Financial Results 4Nile Therapeutics Reports 2010 Third Quarter Financial Results 2Nile Therapeutics Reports 2010 Third Quarter Financial Results 3Nile Therapeutics Reports 2010 Third Quarter Financial Results 4
(Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and retailer, ... . All these items are brand new; they are made ... updated with the new range of high quality prom gowns. ... iFitDress.com’s designs are made according to the latest trends. For ... outfit from the company is handpicked by skilled tailors. , ...
(Date:12/24/2014)... 24, 2014 The federal court ... the blood thinner caused life-threatening episodes of internal ... structure for the proceeding, Bernstein Liebhard LLP reports. ... Court plans to select lawyers to serve as ... on appointing a Plaintiffs’ Steering Committee, which will ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Mike ... sat down with Derek Fenwick, PT, MBA, GCS, ... that will stem from the passing of the ... (IMPACT Act). In this taping of the Infinicast, the ... XVIII of the Social Security Act to standardize post-acute ...
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- Hepatitis C infection does not ... a new study. Treatment advances have made it possible ... develop memory and thinking problems, mood swings and other types ... It,s believed that long-term infections with other viruses -- ... the brain. One of the prime suspects has been the ...
(Date:12/24/2014)... HealthDay Reporter WEDNESDAY, Dec. ... to start smoking or drinking with each additional symptom ... disorder, new research suggests. "Our findings underscore ... substance use as [these] children approach adolescence," said study ... Research Group, which is part of Cincinnati Children,s Hospital. ...
Breaking Medicine News(10 mins):Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Hepatitis C Infection Isn't Related to HIV Brain Woes: Study 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3
... 6 Specialists On Call, Inc. (SOC) announced ... which it provides service, including North Carolina. ... neurology on-call services to hospitals, having already managed ... http://www.newscom.com/cgi-bin/prnh/20081022/LAW515LOGO )Dr. Joe Peterson, CEO, described ...
... Oscar nominated actress reaches goal and inspires millions CARLSBAD, ... the nation,s leading authorities on weight management, announced today ... for 2009. The Grammy award winner and Oscar-nominated ... the brand, playing an active role with the online ...
... is 184th Site in Central RegionDENVER, Colo., Jan. ... or the "Company") (OTC Bulletin Board: GLOB), an ... that its Wyndgate Technologies(R) subsidiary has licensed its ... Hospital of Vincennes, Indiana ("Good Samaritan"). The ...
... Jan. 6 Somanetics Corporation,(Nasdaq: SMTS ) ... and,fiscal year ended November 30, 2008 before the opening ... conjunction with its financial results, the,Company will host a ... a.m.,(ET) the same day. , ...
... 6 Specialists On Call, Inc. (SOC) announced ... which it provides service, including California. SOC ... on-call services to hospitals, having already managed more ... http://www.newscom.com/cgi-bin/prnh/20081022/LAW515LOGO )Dr. Joe Peterson, CEO, described the ...
... consumers are still paying more for out-of-pocket expenses, reports ... to slower spending on prescription drugs, health-care spending in ... a decade in 2007, a new federal report found. ... to rise, with consumers, out-of-pocket expenses having increased 40 ...
Cached Medicine News:Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in North Carolina 2Health News:Queen Latifah to Continue Her Role as Jenny Craig Ambassador 2Health News:Global Med Technologies' Software Chosen to Automate Indiana Hospital Transfusion Center 2Health News:Global Med Technologies' Software Chosen to Automate Indiana Hospital Transfusion Center 3Health News:Global Med Technologies' Software Chosen to Automate Indiana Hospital Transfusion Center 4Health News:Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009 2Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in California 2Health News:Health Care Spending in U.S. Grew at Lowest Rate in a Decade 2Health News:Health Care Spending in U.S. Grew at Lowest Rate in a Decade 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: